Scalp Psoriasis: Causes, Triggers, Treatment — and What Actually Works in 2026
Scalp Psoriasis:
Causes, Triggers, Treatment —
and What Actually Works in 2026
Published reviews report that up to 97% of people with scalp psoriasis say it interferes with their daily life.[2] The thick silvery plaques. The burning itch that doesn't stop. The treatment that works — until you stop using it. This is the complete clinical picture: what drives it, what triggers it, who gets it, why the standard treatment path has a ceiling, and what a comprehensive approach looks like today.
Scalp psoriasis is a chronic autoimmune condition and this article is educational information, not medical advice. Kapyderm products are cosmetic scalp care formulas. They are not drugs, they are not a treatment or cure for psoriasis, and nothing here replaces evaluation and care by a dermatologist or physician. If you have — or think you may have — psoriasis, see a dermatologist. Individual results vary.
Scalp psoriasis is an autoimmune condition driven by the IL-23/IL-17 cytokine axis that produces thick silvery-white plaques, intense itch and burning, and a relapsing cycle that topical-only treatment does not break. Published estimates of scalp involvement in plaque psoriasis range from more than half to up to 80%.[1][6] Commonly documented triggers include stress, infections, alcohol, and vitamin D deficiency. The 2026 treatment landscape includes roflumilast foam (FDA-approved May 22, 2025), biologics, oral TYK2 inhibitors, and cosmetic scalp care systems — including plant-based ones — used alongside medical care to support the scalp surface, barrier and comfort.
- What scalp psoriasis is — and what it looks like
- Prevalence and quality-of-life data
- Symptoms — beyond the flakes
- Triggers — what causes flares
- The IL-23/IL-17 mechanism
- Scalp psoriasis on darker skin tones
- Scalp psoriasis vs dandruff vs seborrheic dermatitis
- Does scalp psoriasis cause hair loss?
- Diet and scalp psoriasis
- The 2026 treatment landscape
- The Dermotricology plant-based routine
- Frequently asked questions
What Scalp Psoriasis Is — and What It Looks Like
Scalp psoriasis is plaque psoriasis occurring on the scalp. It shares the same underlying autoimmune mechanism as psoriasis elsewhere on the body — the immune system drives skin cells to multiply many times faster than normal, producing the characteristic buildup of thick, dead skin cells on an inflamed scalp surface. But the scalp presentation is clinically distinct: harder to reach with topical treatments, frequently refractory to standard approaches, and disproportionately impactful on quality of life relative to the area involved.
On lighter skin tones, scalp psoriasis appears as raised, well-defined, reddish or salmon-colored patches covered with thick silvery-white scales. It frequently extends beyond the hairline onto the forehead, back of the neck, and around and behind the ears.[13] On darker skin tones — including Black, Brown, and Hispanic skin — scalp psoriasis may appear purple, violet, or dark brown, with gray rather than silvery scales. This variation is a recognized cause of misdiagnosis, discussed in detail below.
A 2025 peer-reviewed network meta-analysis of 35 randomized controlled trials opens by stating that scalp psoriasis "is often resistant to topical and conventional systemic agents" and that there is a lack of consensus on a gold standard treatment.[1] Two honest notes on that paper. First, that line is the authors' framing of the problem, drawing on earlier literature — it is not a new finding of the analysis itself. Second, its literature search closed in October 2022, so it does not cover the treatments approved since. What the analysis did find is that among systemic agents, secukinumab 300 mg and bimekizumab 320 mg ranked most effective on the two scalp outcome measures studied.[1]
Prevalence and Quality-of-Life Data
The visibility of the scalp — flakes on every dark shirt, plaques at the hairline — creates a burden that clinical severity scores consistently underestimate. In the National Psoriasis Foundation survey data, 82% said the condition interfered with the enjoyment of life, and 49% of working patients regularly missed work days because of it.[4]
Two caveats worth stating plainly, because most articles do not. The sensitive-scalp figure comes from a research letter describing patients at hospital clinics in Ho Chi Minh City, Vietnam (median age 49, 70.6% male) — a specific population, not a US average. It has also drawn a published objection from other researchers, who argue that sensory symptoms occurring alongside visible plaques do not meet the established definition of sensitive scalp syndrome, which describes discomfort without visible inflammation.[3] And the quality-of-life survey data was collected between 2003 and 2011 and covers psoriasis and psoriatic arthritis together, not scalp psoriasis specifically.[4] The findings are real. The scope is narrower than the headline suggests.
Symptoms — Beyond the Flakes
Scalp psoriasis is frequently reduced to "flaking and itching" in consumer content. The actual symptom profile is significantly more complex — and understanding it matters for both recognition and treatment expectations.
- Thick silvery-white plaques — attached to the scalp surface, often with a dry, silvery scale that lifts off and flakes; on darker skin tones these appear gray rather than silver
- Itch, and often burning — not just surface itchiness; in the 2025 sensitive-scalp study, itching was the most frequently reported sensation at 75.1%, alongside prickling, tightness, pain and burning[3]
- Scalp redness or inflammation — clearly visible on lighter skin; may be subtle or appear as purple/dark discoloration on darker skin
- Extension beyond the hairline — plaques frequently spread onto the forehead, temples, back of the neck, and inside and behind the ears[13]
- Temporary hair thinning — chronic inflammation can disrupt the follicle cycle; this typically improves when the condition is controlled
- Nail changes — pitting, thickening, discoloration, and onycholysis (nail separation) in many psoriasis patients; a key distinguishing feature from seborrheic dermatitis, which does not affect nails[13]
- Sleep disruption — nocturnal itch is a recognized quality-of-life issue in scalp psoriasis
Triggers — What Causes Scalp Psoriasis Flares
Scalp psoriasis is not random. Flares are associated with identifiable factors that activate or amplify the IL-23/IL-17 inflammatory cascade. Identifying and managing your personal triggers is one of the most useful things you can do to reduce flare frequency — alongside whatever treatment your physician has prescribed.[13]
Keeping a simple trigger diary — noting flares alongside stress events, diet changes, weather, sleep, and product changes — is one of the most consistently useful tools for personalizing psoriasis management, and it gives your dermatologist something concrete to work from. The triggers that matter most are specific to the individual, not universal.
The IL-23/IL-17 Mechanism — Why This Is an Autoimmune Condition
Understanding the mechanism isn't just academic — it explains why the relapse cycle exists, why topical-only treatment has a ceiling, and why the most effective pharmaceutical interventions work the way they do.
The cascade: from dendritic cells to plaques
Environmental or genetic triggers activate dendritic cells in the skin. These secrete IL-23 — a cytokine that licenses Th17 T-cells to produce IL-17A and IL-22. IL-17A then drives keratinocyte hyperproliferation, creating the plaque buildup, and generates a feedback loop that sustains the inflammatory environment.[11] Once established, that loop does not require continuous external triggering to keep going.
Topical anti-inflammatories suppress the visible output of this cascade while the upstream immunological loop continues. When you stop, the loop is where it was. The biologics that produce dramatic results work by blocking specific points in the cytokine cascade — which is why their effects last while treatment continues. Their real-world limits are cost, injection or infusion, immunosuppression, and access, which the network meta-analysis names directly.[1] That gap is why many people also want a gentle daily scalp routine alongside medical care. A cosmetic routine is not a substitute for treating the immune driver, and no botanical product blocks IL-17 or IL-23.
Systemic comorbidities — the same pathway, different tissues
The IL-17 pathway driving scalp plaques also contributes to psoriatic arthritis — which develops in up to 30% of psoriasis patients — as well as cardiovascular disease, metabolic syndrome, and depression through shared inflammatory mechanisms.[11] This is the clinical rationale for treating psoriasis as a systemic condition, and it is a conversation to have with a physician rather than a supplement aisle. If you have joint pain alongside psoriasis, raise it at your next appointment.
Scalp Psoriasis on Darker Skin Tones
This is one of the most clinically underserved areas in scalp psoriasis content, and it deserves a section in any comprehensive guide.
On Black, Brown, and Hispanic skin, scalp psoriasis plaques appear purple, violet, or dark brown rather than red, with gray rather than silver scales. Post-inflammatory hyperpigmentation — dark spots remaining after plaques heal — is more pronounced and can persist long after the active disease is controlled. These differences mean it is more easily mistaken for seborrheic dermatitis or "just dandruff."
A widely quoted 2015 Medicare study found Black patients roughly 69% less likely than white patients to receive biologics for psoriasis. A later national analysis of 2003–2018 survey data found no independent association between race and biologic access and was published under that title — so the picture is genuinely disputed.[5] What is more consistently reported is that Black and Hispanic patients describe more misdiagnosis and delayed diagnosis. That is the gap this section is really about.
Special considerations for natural and coily hair types
Standard scalp psoriasis treatment advice is largely designed around straight hair — frequent washing, foam or shampoo-based medicated treatments, leave-on applications. For natural and coily hair types, these routines don't always translate. Washing frequency may be lower; protective styles (braids, locs, weaves) affect product access; and medicated shampoos may strip moisture from hair types already prone to dryness. This is worth raising directly with your dermatologist, since prescribed treatments can often be adapted to a realistic wash schedule. Oil- and cream-based scalp care can be easier to fit around a natural hair routine than a shampoo-only approach — a practical compatibility point, not a claim of superior efficacy.
Whatever route you take, one thing consistently helps: being seen by someone who works with your hair texture regularly. Ask a prospective dermatologist or scalp specialist directly how often they see coily and tightly curled hair. It is a fair question, and the answer tells you a lot.
Scalp Psoriasis vs Dandruff vs Seborrheic Dermatitis
These three conditions are among the most confused in scalp health. They share surface symptoms — flaking, scalp discomfort, redness — but have different underlying mechanisms, which means they need different approaches. Telling them apart on the scalp alone is genuinely difficult, which is why it is a job for a dermatologist rather than a mirror.
| Feature | Scalp Psoriasis | Seborrheic Dermatitis | Dandruff |
|---|---|---|---|
| Mechanism | Autoimmune — IL-23/IL-17 axis | Inflammatory, with Malassezia and barrier disruption involved | Malassezia-associated; mild, no significant inflammation |
| Scale appearance | Thick, dry, silvery-white (gray on dark skin); well-defined plaques | Greasy, yellowish, less-defined patches | Loose white or yellowish flakes; fine, not plaque-like |
| Scalp surface | Red/inflamed underneath (purple on dark skin) | Yellowish, oily background | Normal — no significant inflammation |
| Extends beyond hairline | Often — forehead, neck, ears | Rarely | No |
| Nail changes | Common — pitting, thickening | No | No |
| Joint symptoms possible | Yes — psoriatic arthritis in up to 30% | No | No |
| Under a dermatoscope | Red dots and globules are the characteristic finding | Arborizing red lines and comma vessels | — |
| Can overlap | Psoriasis and seborrheic dermatitis occurring together is described clinically as sebopsoriasis. Recent proteomic work indicates scalp seborrheic dermatitis has its own distinct immune signature rather than being a mild form of psoriasis. | ||
The dermatoscope row above comes from a study comparing 31 scalp psoriasis patients with 112 seborrheic dermatitis patients, which identified red dots and globules as characteristic of psoriasis and arborizing red lines and comma vessels as characteristic of seborrheic dermatitis.[9] A 2025 proteomic study of lesional scalp skin found scalp seborrheic dermatitis carries a distinct inflammatory profile of its own, with Th1 skewing — 16 patients against 12 controls, so early work, but it points away from the idea that the two conditions sit on a single spectrum.[8]
The practical distinction: dandruff generally responds to antifungal shampoos (ketoconazole, zinc pyrithione). Scalp psoriasis does not resolve with antifungal treatment alone, because its driver is autoimmune. If antifungal shampoos haven't resolved your scalp condition after consistent use, that is the point to book a dermatologist rather than to try another shampoo.
Does Scalp Psoriasis Cause Hair Loss?
It can — but in the large majority of cases it is temporary, not permanent. Chronic scalp inflammation can disrupt normal follicle cycling, pushing more follicles into the resting phase and producing increased shedding and reduced density. This typically improves when the condition is controlled — the follicles are dormant, not destroyed.
Permanent scarring alopecia from scalp psoriasis is uncommon, and is associated with very severe, long-standing, untreated disease. For most people managing scalp psoriasis, hair loss is a sign of active disease rather than a prognosis for permanent change.
One underemphasized point: aggressive scratching, picking at plaques, and some treatments can themselves cause hair breakage — independent of the psoriasis. Mechanical gentleness with the scalp during active disease matters more than most people are told.
Diet and Scalp Psoriasis — The Internal Connection
Diet is discussed in psoriasis care through the gut-skin axis and overall inflammatory load. It is a supporting factor rather than a treatment, and the evidence is stronger for some elements — alcohol, vitamin D status, weight — than for others. Nothing below is a substitute for medical care, and dietary changes are worth discussing with your physician, particularly if you take medication for psoriasis.
- Fatty fish (salmon, mackerel, sardines) — a primary dietary source of omega-3 fatty acids
- Colorful vegetables and fruits — the antioxidant-rich core of most anti-inflammatory eating patterns
- Olive oil — a defining component of the Mediterranean pattern
- Vitamin D — deficiency is a documented trigger; ask for a blood test rather than supplementing blind
- Probiotic-rich foods (fermented vegetables, kefir, yogurt) — support gut microbiome diversity
- Whole grains — support insulin sensitivity, relevant given the metabolic comorbidities
- Alcohol — a documented trigger, associated with more frequent flares and reduced treatment response
- Processed and ultra-processed foods — a consistent recommendation across anti-inflammatory dietary advice
- Refined sugars — same rationale
- Red and processed meats — commonly reduced in Mediterranean-pattern eating
- Nightshade vegetables (tomatoes, peppers, eggplant) — reported anecdotally by some patients; this one is individual, not established
The most commonly recommended dietary pattern for psoriasis is the Mediterranean diet, consistent with the priorities above.
Obesity and metabolic syndrome are documented psoriasis comorbidities associated with more severe disease and reduced treatment response. Weight management is clinically relevant here — not as cosmetic advice, but as part of the same inflammatory picture, and best approached with your physician.
The 2026 Treatment Landscape — Honest Assessment
| Option | Mechanism | Evidence | Limitations |
|---|---|---|---|
| Coal Tar (T/Gel, MG217) | Slows keratinocyte hyperproliferation; mildly anti-inflammatory | Recognized for mild scalp psoriasis | Odor; hair discoloration in light hair; potential carcinogenic risk; documented compliance barriers[10] |
| Salicylic Acid (T/Sal, Keralyt) | Keratolytic — softens and lifts scale | Useful for plaque softening; weaker anti-inflammatory action | Can strip the scalp if overused; surface only |
| Clobetasol Shampoo (Clobex) — Rx | Potent corticosteroid — fast suppression of surface inflammation | Strong for moderate-severe; fast clearance | Prescription; HPA axis suppression risk; skin thinning; rebound flare on stopping |
| Roflumilast Foam 0.3% (Zoryve) — Rx May 2025 | PDE-4 inhibitor; steroid-free; once-daily; formulated for hair-bearing areas | FDA-approved May 22, 2025 for scalp and body plaque psoriasis, ages 12+, on the phase 3 ARRECTOR and phase 2 trials (736 participants)[6] | Prescription; topical only; long-term data still accruing |
| Biologics (Skyrizi, Taltz, Cosentyx, Tremfya) | IL-17/IL-23 blockade — targets the systemic driver directly | Strong for moderate-severe. Risankizumab has published phase 4 week-16 results specifically in scalp psoriasis, and the FDA updated its US label with that data in March 2026[7] | High cost; injection or IV; immunosuppression; documented access barriers[1] |
| Oral TYK2 inhibitors (Sotyktu) Emerging | Blocks TYK2 — oral, no injection | Phase 3b/4 scalp psoriasis data has been published | Prescription; newer safety data |
| Kapyderm scalp care routine | Cosmetic scalp care: keratolytic support to soften surface scale, plus cleansing, botanical soothing and emollient barrier support | No controlled trial evidence in scalp psoriasis. Cosmetic scalp care for daily comfort, used alongside medical treatment — not instead of it | Not a drug · not a treatment for psoriasis · no prescription and no medical claim |
The Dermotricology Plant-Based Routine
What follows is a cosmetic scalp care routine, not a treatment for psoriasis. It is designed around comfort and the condition of the scalp surface: softening built-up scale so the scalp can be cleansed gently, supporting the skin barrier, and keeping the scalp environment balanced day to day. People with psoriasis often use a routine like this alongside what their dermatologist has prescribed. Tell your dermatologist what you are using, and patch-test anything new.
Phase 1 — Daily care during an active flare
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Food supplements do not replace a varied diet or prescribed medication. If you are taking any medication for psoriasis — particularly an immunosuppressant or biologic — tell your prescribing physician about every supplement you take before you start.
Phase 2 — Ongoing scalp maintenance
Once scale buildup has cleared and the scalp is more comfortable, the routine simplifies to daily upkeep.
Frequently Asked Questions
- Kaur H, Behroozian T, Lansang RP, Caini S, Doccioli C, Abu-Hilal M. Biologic and Non-Biologic Therapies for Scalp Psoriasis: A Network Meta-analysis of Randomized Controlled Trials. Dermatology Practical & Conceptual. 2025;15(2):4793. doi:10.5826/dpc.1502a4793. PMID 40401874. Literature search closed October 5, 2022. PMC12090945
- Crowley J. Scalp psoriasis: an overview of the disease and available therapies. Journal of Drugs in Dermatology. 2010;9(8):912–918. PMID 20684141. Original source of the "up to 97% report interference with daily life" figure quoted in ref. 1.
- Pham N, Nguyen CTH, Van TT. Sensitive scalp syndrome in scalp psoriasis: prevalence, correlates, and quality-of-life impact. JAAD International. 2025;24:248–249. doi:10.1016/j.jdin.2025.11.001. Research letter; multicenter cross-sectional study in Ho Chi Minh City, Vietnam, August 2024–June 2025; 350 patients. A published response from Brenaut et al. disputes whether these sensory symptoms meet the definition of sensitive scalp syndrome.
- Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011. PLOS ONE. 2012;7(12):e52935. PMID 23285231. 5,604 patients with psoriasis or psoriatic arthritis. journals.plos.org
- No Racial Differences Found in Access to Biologics: A Population-Based Study of Psoriasis Patients in the United States. Journal of Drugs in Dermatology. 2023. Medical Expenditure Panel Survey 2003–2018. This paper both cites the earlier 2015 Medicare finding of 69% lower biologic use among Black patients and reports contrary findings in its own national sample. jddonline.com
- Arcutis Biotherapeutics. ZORYVE (roflumilast) topical foam 0.3% approved by U.S. FDA for the treatment of plaque psoriasis in adults and adolescents ages 12 and older. Company press release, May 22, 2025. Source of the FDA approval date and the "more than half of the nearly 9 million people in the United States with plaque psoriasis" figure. arcutis.com
- Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16. Study-S is the scalp arm. PMC12872952
- Shen N, Chen W, Hu L, Huang J, Dong Q. Scalp seborrheic dermatitis demonstrates a skewing of Th1 activation: a proteomic study in lesional skin. Frontiers in Immunology. 2025;16:1638710. doi:10.3389/fimmu.2025.1638710. 16 patients, 12 controls, 92 inflammatory biomarkers. frontiersin.org
- Kibar M, Aktan Ş, Bilgin M. Dermoscopic Findings in Scalp Psoriasis and Seborrheic Dermatitis; Two New Signs; Signet Ring Vessel and Hidden Hair. Indian Journal of Dermatology. 2015;60(1):41–45. doi:10.4103/0019-5154.147786. PMID 25657395. 31 scalp psoriasis and 112 seborrheic dermatitis patients. PMC4318061
- Scalp Psoriasis: A Literature Review of Effective Therapies and Updated Recommendations for Practical Management. Source of the documented coal tar compliance barriers. PMC8163911
- Interleukin-17 and Interleukin-23: mechanisms in psoriasis and its comorbidities. Source of the IL-23/IL-17 cascade description and the psoriatic arthritis comorbidity figure. PMC8019008
- Ge S, et al. Salicylic acid in scalp seborrheic dermatitis. 20 participants, uncontrolled. PMC11705510
- National Psoriasis Foundation. Scalp Psoriasis. Patient education resource — overview, symptoms, causes, triggers, treatment. psoriasis.org
- JMIR Dermatology. Google Trends in Dermatology: A Scoping Review. Search-volume data showing seasonal variation in psoriasis searches, elevated in late winter and early spring. Search interest is an indirect signal, not a clinical measurement. derma.jmir.org
14 sources: 9 peer-reviewed journal articles, 1 company press release (ref. 6, used only for the FDA approval date and the company's own prevalence figure), 1 patient-education resource, and 1 search-volume review. Where sources disagree — on scalp involvement rates and on racial disparities in biologic access — this article states the disagreement rather than picking a number. There is no controlled trial of any Kapyderm product in scalp psoriasis. Last reviewed August 2026.
A Gentle Daily Scalp Routine.
No Steroids. No Coal Tar.
The Kapyderm scalp care range is a plant-based cosmetic system for daily scalp comfort — softening surface scale, gentle cleansing, and barrier support. EU-regulated, suitable for all skin tones and hair types, and made to sit alongside the care your dermatologist provides rather than replace it.
